Loading...
XASX
CBL
, Last price  
AUD
Name

Control Bionics Ltd

Chart & performance

D1W1MN
XASX:CBL chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
32.01%
Rev. 5Y
3.12%
Div Yld LY
—
Div Yld TTM
—
Revenues
5m
-22.43%
0232,893,700311,292,912805,415781,4473,099,0924,088,4604,501,8905,642,3865,350,7746,144,9074,766,730
Net income
-7m
L+18.94%
033,284,19528,603,069-972,455-1,931,652-1,005,500-3,550,826-6,110,111-5,631,141-5,913,779-6,108,667-7,265,603
CFO
-6m
L+34.65%
00-970,843-1,945,374-864,049-3,990,634-6,886,935-4,527,388-4,911,898-4,269,320-5,748,767

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating in Australia and North America, Control Bionics Limited and its subsidiaries specialize in the innovation, development, and market introduction of sophisticated assistive communication technologies. The company's offerings include the NeuroNode Trilogy and NeuroNode3 systems, which empower individuals facing speech and mobility challenges to control computers for speech generation, electronic correspondence, leisure activities, and remote operation of other devices. Control Bionics also provides Cosmos Connect, a versatile interface capable of managing diverse equipment like wheelchairs, robotic dining aids, and gaming consoles. Additionally, they offer Uno Touch, a dedicated speech-generating device, alongside various other sensors for a broad spectrum of uses. Founded in 2005, the entity was initially named Control Bionics Holdings Pty Limited before rebranding as Control Bionics Limited in September 2020. The company's base of operations is situated in Camberwell, Australia.
IPO date
Dec 07, 2020
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT